Johnson & Johnson $JNJ Stake Lifted by One Degree Advisors Inc

One Degree Advisors Inc increased its stake in Johnson & Johnson (NYSE:JNJ) by 28.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,594 shares of the company’s stock after acquiring an additional 350 shares during the period. One Degree Advisors Inc’s holdings in Johnson & Johnson were worth $243,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth approximately $35,000. Highline Wealth Partners LLC lifted its position in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $48,000. Finally, von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $49,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.88 on Tuesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10. The firm’s fifty day simple moving average is $178.88 and its 200 day simple moving average is $163.97. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $459.71 billion, a PE ratio of 20.42, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion for the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on JNJ shares. Citigroup increased their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a report on Friday, October 3rd. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $192.94.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.